These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3954159)

  • 1. A new, ideal technique to monitor thrombolytic therapy.
    Görög P
    Angiology; 1986 Feb; 37(2):99-105. PubMed ID: 3954159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Thrombolytics and their use].
    Alessi MC; Juhan-Vague I
    Rev Prat; 1999 Oct; 49(15):1654-8. PubMed ID: 10581996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current developments in thrombolytic therapy using novel plasminogen activators.
    Seifried E; Tanswell P
    Arzneimittelforschung; 1989 Nov; 39(11):1474-82. PubMed ID: 2695093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostacyclin is a more potent stimulator of thrombolysis than inhibitor of haemostasis.
    Görög P; Kovacs IB
    Haemostasis; 1986; 16(5):337-45. PubMed ID: 3536684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
    Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M
    J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombolytic therapy.
    Collen D; Stump DC; Gold HK
    Annu Rev Med; 1988; 39():405-23. PubMed ID: 3130773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolytic agents and their effects on the haemostatic system.
    Kluft C
    Klin Wochenschr; 1988; 66 Suppl 12():50-4. PubMed ID: 2964542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered in vitro hemostasis, clotting, and thrombolysis after oral nifedipine in normal volunteers.
    Rademaker M; Meyrick-Thomas RH; Kirby JD; Kovacs IB
    Angiology; 1988 Aug; 39(8):747-51. PubMed ID: 3421508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
    Puri RN; Colman RW
    Blood Coagul Fibrinolysis; 1993 Jun; 4(3):465-78. PubMed ID: 8329574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hematologic consequences of thrombolytic therapy.
    Fletcher AP; Alkjaersig NK
    Prog Hematol; 1986; 14():183-200. PubMed ID: 2935903
    [No Abstract]   [Full Text] [Related]  

  • 12. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D; Bounameaux H
    Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of somatostatin on haemostasis in dogs.
    Gabryelewicz A; Prokopowicz J; Hnidec O; Wolosowicz N
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(1):125-31. PubMed ID: 6164606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Present-day thrombolytic therapy: therapeutic agents--pharmacokinetics and pharmacodynamics.
    Bell WR
    Rev Cardiovasc Med; 2002; 3 Suppl 2():S34-44. PubMed ID: 12556741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locally delivered plasmin: why should it be superior to plasminogen activators for direct thrombolysis?
    Novokhatny VV; Jesmok GJ; Landskroner KA; Marder VJ; Zimmerman TP
    Trends Pharmacol Sci; 2004 Feb; 25(2):72-5. PubMed ID: 15102492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of new thrombolytic substances].
    Zeymer U; Neuhaus KL
    Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1.
    Dong N; Da Cunha V; Citkowicz A; Wu F; Vincelette J; Larsen B; Wang YX; Ruan C; Dole WP; Morser J; Wu Q; Pan J
    Thromb Haemost; 2004 Nov; 92(5):956-65. PubMed ID: 15543321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinolytic enzyme system and pregnancy.
    Bonnar J; McNicol GP; Douglas AS
    Br Med J; 1969 Aug; 3(5667):387-9. PubMed ID: 5797779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The search for the ideal thrombolytic agent: maximize the benefit and minimize the risk.
    Gardell SJ
    Toxicol Pathol; 1993; 21(2):190-8. PubMed ID: 8210941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.